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Background: Previously, we identified multiple, rare serotonin (5-HT) transporter (SERT) variants in children with
autism spectrum disorder (ASD). Although in our study the SERT Ala56 variant was over-transmitted to ASD
probands, it was also seen in some unaffected individuals, suggesting that associated ASD risk is influenced by the
epistatic effects of other genetic variation. Subsequently, we established that mice expressing the SERT Ala56
variant on a 129S6/S4 genetic background display multiple biochemical, physiological and behavioral changes,
including hyperserotonemia, altered 5-HT receptor sensitivity, and altered social, communication, and repetitive
behavior. Here we explore the effects of genetic background on SERT Ala56 knock-in phenotypes.
Methods: To explore the effects of genetic background, we backcrossed SERT Ala56 mice on the 129 background
into a C57BL/6 (B6) background to achieve congenic B6 SERT Ala56 mice, and assessed autism-relevant behavior,
including sociability, ultrasonic vocalizations, and repetitive behavior in the home cage, as well as serotonergic
phenotypes, including whole blood serotonin levels and serotonin receptor sensitivity.
Results: One consistent phenotype between the two strains was performance in the tube test for dominance,
where mutant mice displayed a greater tendency to withdraw from a social encounter in a narrow tube as
compared to wildtype littermate controls. On the B6 background, mutant pup ultrasonic vocalizations were
significantly increased, in contrast to decreased vocalizations seen previously on the 129 background. Several
phenotypes seen on the 129 background were reduced or absent when the mutation was placed on the B6
background, including hyperserotonemia, 5-HT receptor hypersensivity, and repetitive behavior.
Conclusions: Our findings provide a cogent example of how epistatic interactions can modulate the impact of
functional genetic variation and suggest that some aspects of social behavior may be especially sensitive to
changes in SERT function. Finally, these results provide a platform for the identification of genes that may modulate
the risk of ASD in humans.
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The serotonin (5-hydroxytryptamine, 5-HT) system has
long been implicated in Autism Spectrum Disorder (ASD)
[1]. Elevated whole blood 5-HT, termed hyperserotonemia,
is found in about 30% of ASD patients [2,3]. Blood 5-HT
levels are more heritable than ASD itself [4-7], but the link* Correspondence: j.vvw@vanderbilt.edu
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reproduction in any medium, provided the orbetween hyperserotonemia and ASD pathophysiology has
remained elusive. In the blood, 5-HT is found almost
exclusively in platelets that cannot produce 5-HT, but take
it up via the antidepressant-sensitive 5-HT transporter
(SERT). Peripheral serotonin is synthesized and released
by enterochromaffin cells that release 5-HT into the en-
teric circulation. Consistent with a primary role in platelet
5-HT uptake, polymorphisms in the SERT gene (SLC6A4)
have been associated with human whole blood 5-HT
levels; however, this has been observed only in males and
not females [8], with a similar pattern observed for the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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age studies have implicated the chromosome 17q region
containing SLC6A4 in ASD, also with stronger evidence in
males [11-15].
In contrast to linkage studies, multiple groups have
found, at most, modest association between common
SLC6A4 variants and ASD [16-18]. Allelic heterogeneity
may account for difficulty in assessing association in this
region. Indeed, multiple common functional variants have
been identified in the SLC6A4 gene (reviewed in [19]). We
identified multiple, rare SERT coding variants in ASD
families with evidence of linkage to 17q. We also found
that the most common of these variants, SERT Ala56,
was significantly associated with rigid-compulsive behavior
and sensory aversion. Lending credence to a functional
contribution of the SERT variants identified, each of
the variants was found to confer increased 5-HT transport
activity in cell models relative to wildtype SERT [14,20,21].
In our study, the Ala56 variant showed an approximately
2:1 transmission bias to affected versus unaffected chil-
dren [14]. Importantly, however, some variant carriers
were unaffected by ASD, and a case–control study has
reported no association of ASD with rare SERT amino
acid variants in the absence of linkage [22], indicating
that other genetic or non-genetic risk factors likely impact
the resulting phenotype.
To assess the functional relevance of the SERT Ala56
variant in vivo, we produced knock-in mice, expressing
the variant on a 129S6/S4 inbred background. In these
mice, we observed multiple biochemical and behavioral
phenotypes that recapitulate some features of ASD,
including hyperserotonemia, altered social function in
the tube test and three-chamber sociability test, decreased
ultrasonic vocalizations, and repetitive climbing/hanging
behavior in the home cage [23]. We also observed
hypersensitivity to in vivo activation of 5-HT1A and 5-HT2A
receptors, reasonably attributable to diminished synaptic
5-HT availability and functional upregulation of 5-HT
receptors. Unfortunately, this inbred strain background
shows a low level of activity in novel environments across
multiple behavioral tests [23], which limits the assessment
of anxiety-like and social behaviors that are dependent
upon spontaneous locomotion.
As 5-HT is a modulator of multiple CNS pathways
subserving complex behaviors, we suspected that SERT
coding variation could be influenced by genetic variation
in other genes, which might account for the variable
phenotype observed in humans with the SERT Ala56
allele. To explore this issue, we moved the SERT Ala56
allele to a C57BL/6 (B6) background for two purposes:
1) to examine autism-relevant behavior in a more active
and social strain than 129, and 2) to study strain depend-
ence of SERT function, the 5-HT system, and resulting be-
havior. Previous work identified a functional and behavioralimpact of variation at two amino acids that differ between
129 and B6 inbred strains [24]. We therefore also
backcrossed the 129 SERT onto the B6 background to
allow a comparison with the mutant SERT on this
background. Our findings reveal a striking influence of
genetic background on the impact of the SERT Ala56
variant, suggesting that further dissection of strain differ-
ences could illuminate other genes modulating risk of ASD.
Methods
Mice
All animal procedures were in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Vanderbilt
University Institutional Animal Care and Use Committee.
Backcross
Male SERT Ala56 mice (Glu39/Ala56/Arg152) on a
mixed 129S6/SvEvTac and 129S4/ImJ background [23]
were crossed with B6 females, with male progeny from
each generation crossed again to B6 females for at least
eight generations. The Jackson Lab Genome Scanning
Service (Bar Harbor, ME, USA) was used to verify
congenic status with B6. In parallel, wildtype 129S6/S4
mice from the same colony (SERT Glu39/Gly56/Arg152)
were backcrossed at least ten generations to B6 and
verified congenic with B6 to serve as valid control an-
imals. SERT Gly56Ala and SERT Arg152/Lys genotyp-
ing was performed as described previously [23,24].
Sanger sequencing, as described previously, was used to
verify that the SERT Ala56 was maintained after the full
backcross [25].
Behavioral testing
Co-housed littermate progeny of heterozygous pairs
(SERT Gly56/Ala56) were used for all behavioral testing.
A cohort of 20 matched male Ala56/Ala56 and Gly56/
Gly56 littermates, as well as 16 co-housed matched male
Ala56/Gly56 littermates, was used in behavioral exper-
iments in the following order to minimize order effects
on testing [26,27]: elevated zero maze, light–dark test,
open field activity, three-chamber sociability test, tube test,
Y maze spontaneous alternation, and von Frey filament
test. A subset of this cohort was used for home cage
monitoring (12 Ala56/Ala56 and 12 Gly56/Gly56). A co-
hort of 20 matched female Ala56/Ala56, Ala56/Gly56,
and Gly56/Gly56 littermates was used in behavioral
experiments in the following order: elevated zero maze,
light–dark test, and open field activity.
Elevated zero maze
Assessment of anxiety-like behaviors were evaluated using
an elevated zero maze, as described previously [28] for 5
minutes under standard fluorescent light.
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Anxiety-like responses were evaluated using activity
monitors (Med Associates, Inc., St. Albans, VT, USA)
divided in half to create a light compartment and a dark
compartment, as described previously [29], with the subject
mouse being placed in the light compartment at the begin-
ning of the test and activity recorded for 5 minutes.
Open field activity
Exploratory locomotor activity was evaluated in activity
monitors (Med Associates, Inc., St. Albans, VT, USA), as
described previously [23].
Three-chamber sociability and preference for social
novelty test
Social behavior was evaluated in a three-chamber poly-
carbonate apparatus with 4-inch sliding gates separating
the 7 × 9-inch chambers, as described previously [23,30].
The subject mouse was initially allowed to explore all three
chambers for 10 minutes to acclimate to the apparatus.
A stimulus mouse (social stimulus) was then introduced
inside an inverted wire pencil cup (Spectrum Diversified
Designs, Streetsboro, OH, USA) in one side chamber with
a clean empty pencil cup (inanimate stimulus) introduced
in the opposite side chamber. The stimulus mouse was
an adult male 129S4/ImJ mouse, previously habituated
to the pencil cup in six 30-minute sessions across 3
days. The subject mouse was then allowed to explore
all three chambers for 10 minutes. A new stimulus
mouse was then introduced inside a pencil cup in the
previous inanimate stimulus chamber. The subject mouse
was finally allowed to explore all three chambers for 10
minutes. A research assistant blinded to mouse geno-
type coded videos for time spent in each chamber and
within 1 cm of each pencil cup.
Tube test
The tube test was conducted in male mice as described
previously [23]. The apparatus is a 30-cm-long, 3.5-cm-
diameter clear acrylic tube with small acrylic funnels
added to each end to facilitate entry into the tube. Mice
were preconditioned to the tube to reduce novelty ef-
fects and ensure that they will readily enter and progress
forward through the tube. On two separate days before
testing, each mouse was exposed to the tube, with progress
through the tube resulting in the mouse being returned
to the home cage. Mice that did not initially enter the
tube were encouraged to run forward with a gentle pull
of the tail. For each bout, a mouse was paired with a
stranger mouse from a different cage. The ‘winner’
mouse was declared when the other mouse backed out
of the tube. Trials were repeated from the opposite end
to avoid a side bias. Each mouse was tested against four
to five individuals from other cages.Home cage monitoring
To evaluate possible repetitive behavior, 12 Ala56/Ala56
and 12 Gly56/Gly56 mice were video-recorded alone in
their home cage for 24 hours while maintaining their light/
dark schedule, as described previously [23]. Automated
video analysis was conducted by using HomeCageScan
(CleverSys, Inc., Reston, VA, USA) to index time spent
performing individual behaviors. The resulting data
were condensed into 10 individual behaviors: awaken/
sleep, chew/eat/drink, rear, groom, hang, remain low,
sniff, stretch, twitch, and walk. To normalize distributions
for analysis, data were log10-transformed. Bouts of hanging
behavior were defined as distinct periods of hanging
from the wire lid of the cage separated by non-hanging
behaviors. The number of bouts per animal was also
log10-transformed for analysis.
Y-maze
To evaluate for perseverative exploratory behavior,
mice were tested for spontaneous alternation in the
Y-maze, with maze arms of 6 × 35.5 cm, as previously
described [31]. The subject mouse was placed facing
the center in one of the three arms of the maze and
then allowed to explore for 6 minutes. Each trial was
video recorded and then scored for spontaneous alter-
nation, which was defined as entry into a different arm
than on the previous two entries.
von Frey
Tactile sensitivity was assessed using plastic von Frey
monofilaments applied to plantar surface of the sub-
ject’s right hind paw [32]. Briefly, each subject was
placed into a plexiglass chamber with a wire mesh
flooring for experimental access to the mouse footpad.
Subjects were allowed to habituate to the testing chamber
for 5 minutes before the assessment of tactile sensitivity.
Von Frey monofilaments (Stoelting Co., Wood Dale, IL,
USA) of ascending diameter were applied to the subject’s
hind paw until reaching the target force (that is, bending
of the filament). The lowest force required to elicit a
paw withdrawal response was considered a subject’s
tactile sensitivity threshold.
Resident intruder
A subset of 18 male mice of each homozygous genotype
was used, with two littermate cages removed due to pre-
vious fighting injuries. The test mouse, the resident, was
isolated in its home cage for 7 days. A novel mouse, the
intruder, was then introduced to the resident’s home cage
for 5 minutes. The intruder was an adult male 129S4/ImJ
mouse. Interactions were recorded and a researcher blind
to genotype scored videos for time of the initial aggressive
behavior of the resident.
Kerr et al. Molecular Autism 2013, 4:35 Page 4 of 11
http://www.molecularautism.com/content/4/1/35Ultrasonic vocalization
Progeny of heterozygous SERT Ala56/Gly56 pairs at
postnatal day 7 were used to measure ultrasonic vocali-
zations, as described previously [23]. Pups were removed
from their cage and placed in a Styrofoam chamber
with bedding. Ultrasonic vocalizations were measured
for 5 minutes using a Condenser ultrasound microphone
(Avisoft-Bioacoustics, Berlin, Germany) and Avisoft SASLab
Pro software (Avisoft-Bioacoustics, Berlin, Germany).
Thresholds were set to detect only small frequency-
modulated vocalizations within a 250-kHz range lasting
at least 5 ms and occurring at least 20 ms apart.
Dimethoxy-4-iodoamphetamine-induced head twitch
response
A separate cohort of 12 littermate pairs was used to
evaluate head twitch response to 2,5-dimethoxy-4-
iodoamphetamine (DOI), as described previously [23].
Briefly, each mouse was administered an intraperitoneal
injection of 1.0 mg/kg DOI (Sigma-Aldrich, St. Louis, MO,
USA) and then allowed to acclimate to a standard housing
cage with clean bedding for 34 minutes. Two research
assistants who were blind to genotype then independently
counted head twitches over 15 minutes.
8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia
A separate cohort of 10 littermate pairs was used to evaluate
hypothermia response to 8-hydroxy-2-(di-n-propylamino)
tetralin (8-OH-DPAT). Briefly, core temperature was mea-
sured every 10 minutes for 80 minutes with a rectal probe
(no. 50314; Stoelting, Wood Dale, IL, USA) connected
to a BAT-12 thermometer (Physitemp Instruments,
Clifton, NJ, USA). Immediately after the third temperature
measurement, mice were administered a subcutaneous
injection of 0.1 mg/kg 8-OH-DPAT (Sigma-Aldrich, St.
Louis, MO, USA).
Whole blood and midbrain harvest
Twelve SERT Ala56 mice and matched littermate controls
at postnatal day 7 were rapidly decapitated and trunk blood
was collected in 1.5 ml microcentrifuge tubes containing
37 USP units of lithium heparin and mixed by inversion.
Samples were immediately placed on dry ice and then
stored at -80°C until analysis.
High-performance liquid chromatography
High-performance liquid chromatography (HPLC) was
conducted as described previously [33]. Briefly, an internal
standard solution (ISS) containing N-methylserotonin,
ascorbic acid and sodium metabisulfite was added to the
samples. After samples were vortex mixed, perchloric acid
was added to the samples, which were mixed and then
kept on ice for 10 minutes prior to centrifugation at 6000 g
for 5 minutes. The supernatant was removed and storedat −80°C until analyzed by HPLC with fluorometric
detection. Serotonin was determined with intra- and
inter-assay coefficients of variation of less than 5 and
10%, respectively.
Synaptosome 5-HT Uptake
Synaptosomes were prepared as described previously [34].
Briefly, 5-HT uptake was determined at 20 nM and 100 nM
with tritiated 5-HT (Perkin Elmer, Waltham, MA, USA).
Serotonin uptake was conducted at 37°C for five minutes,
with SERT-specific uptake determined by subtracting
S-citalopram blocked non-specific uptake. Resulting uptake
data were normalized to total protein.
Statistics
The primary analysis for each comparison was SERT
Gly56/Gly56 versus SERT Ala56/Ala56. Paired t-tests
were used for littermate pair comparisons, except where
noted. For experiments that included heterozygous an-
imals, secondary analysis with one-way ANOVA was
used to evaluate overall effects of genotype, with post-hoc
Bonferroni testing used only when the main effect or
interaction was significant. For the three-chamber so-
ciability test, repeated-measures ANOVA, excluding
the center chamber, was used to evaluate social versus
novel object for each genotype. All statistical analyses were
performed on GraphPad Prism (La Jolla, CA, USA) or
on the accompanying website.
Results
As our previous work identified two sites of functional,
coding variation in SERT between 129 and B6 inbred
strains (Glu39Gly; Arg152Lys) [24], it was necessary to
backcross 129-derived animals expressing wildtype Gly56
SERT in parallel with engineered 129 animals expressing
SERT Ala56 onto the B6 background to permit a proper
analysis of the unique effects of the Ala56 variant. This
effort yielded animals with >99% C57BL/6 strain identity.
A female C57BL/6 SERT ER-Gly56 mouse (SERT Glu39/
Gly56/Arg152, hereafter described as Gly56) was bred
with a male C57BL/6 SERT ER-Ala56 mouse (SERT
Glu39/Ala56/Arg152, hereafter described as Ala56) to
establish animals heterozygous for the SERT Ala56
variant, permitting the generation of homozygous Gly56/
Gly56, heterozygous Gly56/Ala56, and homozygous Ala56/
Ala56 littermates used in the experiments reported.
Whereas we found the 129-expressed Ala56 variant to
induce no changes in locomotor activity in a novel environ-
ment, as assessed in the open field test [23], we detected a
small but significant decrease in activity in homozygous
male Ala56 animals on the B6 background, both for
total ambulatory time (t = 3.45, P = 0.003) and ambulatory
distance (t = 3.11, P = 0.006) (Figure 1A, [see Figure S1






































































Figure 1 Activity and anxiety-like behavior in male B6 SERT Ala56 knock-in mice. A) Time (mean, standard error of the mean) spent
ambulating during the first 5 minutes in the open field for wildtype littermate controls (G/G, n = 20), heterozygous (A/G, n = 16), and
homozygous (A/A, n = 20) SERT Ala56 mice; B) Time spent in the center (>1 cm away from the side) of the open field divided by total time in
the open field; C) Time spent in the open zone divided by total time in the elevated zero maze; D) Time spent in the light chamber divided by
total time in the light–dark test. *P <0.05.
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Additional file 2; See Figure S3 in Additional file 3].
Results for anxiety-like behavior conflicted across three
tests. The ratio of time spent in the center of the open
field, compared to total time, over the first five minutes of
the test was not different in males (t = 0.97, P = 0.35) or
females (t = 0.79, P = 0.44) (Figure 1B, [See Figure S2 in
Additional file 2]). Similarly, no difference was seen in the
time spent in the open arms of the Elevated Zero Maze
over 5 minutes for males (t = 0.79, P = 0.44) or females
(t = 1.52, P = 0.15) (Figure 1C, [See Figure S2 in Additional
file 2]). In contrast, a genotype effect was observed
with SERT Ala56 males spending less time in the light
compartment of the light–dark test than homozygous
Gly56 littermates (t = 2.51, P = 0.02) (Figure 1D). Again, fe-
males displayed no difference in this test (t = 1.55, P = 0.15)
[See Figure S2 in Additional file 2].
Results on social testing were also mixed. In the
three-chamber sociability test, all three genotypes showed
a significant preference for the social stimulus over the
non-social stimulus, both when chamber time was recorded
(overall stimulus F = 96.6, P <0.0001 for each genotype)
and when time <1 cm from the stimulus mouse was
recorded (overall stimulus F = 135.1, P <0.0001 for each
genotype) (Figure 2A,B). On the preference for social
novelty portion of the three-chamber test, the Gly56 animal
showed no significant preference for the novel social
stimulus [See Figure S1 in Additional file 1], which makesthe comparison data uninterpretable. On the tube test,
homozygous Ala56 animals showed a significant propensity
to back out of the tube when encountering a homozygous
Gly56 animal (McNemar’s exact test P <0.0001; n = 126
encounters), as well as when encountering a Ala56/Gly56
animal (P <0.0001; n = 119 encounters) (Figure 2C,D).
No difference was detected when heterozygous Ala56/
Gly56 encountered Gly56/Gly56 animals (P = 1.0, n = 93
encounters) (Figure 2E). On the resident-intruder test,
we observed no difference in latency to attack between
genotypes (t = 0.41, P = 0.69) (Figure 2F). Similarly, of
the homozygous Ala56 animals, 13/18 showed aggression
toward the intruder during the 10-minute test period,
as compared to 10/18 homozygous Gly56 animals (Fisher’s
exact test P = 0.49).
In our prior study on the 129 background, we found
decreased ultrasonic vocalizations (USVs) in homozygous
Ala56 pups when separated from the dam at postnatal day
7. In contrast, on the B6 background, homozygous Ala56
pups displayed increased USVs in comparison to wildtype
littermate controls (Mann–Whitney U = 368.5, P = 0.017)
(Figure 2G). Secondary Kruskal-Wallis comparison of all
three genotypes showed a trend for an overall genotype
effect (K-W 5.59, P = 0.06).
No changes in repetitive or sensory behavior were
induced by the Ala56 variant on the B6 background.
Behavior in the home cage did not show any differences









































































































Figure 2 Social behaviors and pup ultrasonic vocalizations in male B6 SERT Ala56 knock-in mice. A) Time (mean, standard error of the mean)
spent in the social stimulus chamber (novel mouse), center chamber, or inanimate stimulus chamber (novel object) in the three-chamber sociability
test for wildtype littermate controls (G/G, n = 20), heterozygous (A/G, n = 16), and homozygous (A/A, n = 20) SERT Ala56 mice; B) Time spent within
1 cm of the social stimulus or inanimate stimulus in the three-chamber sociability test; C) Total number of wins (frontward exit) for pairings of wildtype
littermate controls (G/G) and homozygous SERT Ala56/Ala56 (A/A) mice in the tube test confrontation; D) Total number of wins for heterozygous (A/G)
versus homozygous SERT Ala56 (A/A) mice when paired in the tube test; E) Total number of wins for wildtype (G/G) versus heterozygous SERT Ala56
(A/G) mice when paired in the tube test; F) Latency to attack a wildtype 129S4 intruder mouse introduced into the cage of a resident subject mouse
who had been singly housed for 7 days (n = 16 per genotype); G) Pup vocalizations upon separation from the dam for 5 min at postnatal day 7 for
wildtype littermate controls (G/G, n = 36), heterozygous (A/G, n = 65), and homozygous SERT Ala56 (A/A, n = 33) mouse pups. *P <0.05.
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tween the genotypes when hanging behavior, which
was increased on the 129 background, was considered
alone (t = 0.35, P = 0.73) (Figure 3B). Importantly, this
behavior was less prevalent on the B6 background in
general in comparison to the 129 background [23]. Further,
no differences were observed in spontaneous alternations
on the Y maze (t = 1.20, P = 0.25) (Figure 3C) nor in tactile
sensitivity assessed using reaction to von Frey filaments
(t = 0.07, P = 0.95) (Figure 3D).
Since we observed evidence of a genetic background
effect on behavioral phenotypes, we examined whether
Ala56-induced serotonergic phenotypes were preserved.On the B6 background, we observed no genotype influ-
ences on adult male whole blood 5-HT levels (Figure 4A).
To decrease variability and maximize sensitivity to
detect a differences, we moved to a fluorometric de-
tection method at post-natal day 7 [35] and here ob-
served a trend for higher whole blood 5-HT levels in
males, but only when we performed a one-tailed test
(t = 1.64, P = 0.058, n = 12 per genotype) (Figure 4B).
No difference in whole blood 5-HT levels was observed
with females (one-tailed t = 0.27, P = 0.40, n = 12 per
genotype) [See Figure S4 in Additional file 4]. Other







































































































Figure 3 Home cage, exploratory, and sensory behavior in male B6 SERT Ala56 knock-in mice. A) Time (mean, standard error of the
mean) spent performing individual non-sleep behaviors over 24 hours in the home cage in wildtype littermate controls (G/G, n = 12) and
homozygous (A/A, n = 12) SERT Ala56 mice; B) Number of bouts of hanging behavior in 24 hours in the home cage; C) Ratio of spontaneous
alternations, defined as entering a different arm than on the previous two entries, divided by total entries in the Y maze (n = 20 per genotype);
D) Force threshold at which the paw is moved upon bending of the von Frey filaments (n = 20 per genotype).
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also suggested an attenuated impact of the Ala56 variant
on a B6 background. Midbrain synaptosome 5-HT uptake
showed no significant difference between genotypes
at either 20 nM (t = 0.11, P = 0.93) or 100 nM of 5-HT
(t = 2.93, P = 0.10) (Figure 4C,D). Since ex vivo synap-
tosome studies may not reproduce changes in 5-HT
systems in vivo, we also assessed the impact of intra-
peritoneal (i.p.) injections of 5-HT receptor agonists
[23]. In contrast to our prior findings, injection of the
5-HT2A/2C agonist 2,5-dimethoxy-4-iodoamphetamine
(DOI) induced a similar number of head twitches in Ala56
and Gly56 animals (t = 0.79, P = 0.44) (Figure 4E). Similarly,
no significant difference was observed between the geno-
types in the maximum hypothermia response to injection
of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)
tetralin (8-OH-DPAT) (t = 0.16, P = 0.87) (Figure 4F).
Discussion
Strain comparisons have been profitably used to identify
quantitative trait loci (QTLs) and specific genes that
modify traits, as for example with the recombinant inbred
(RI) mouse reference panel derived from C57BL/6 and
DBA2/J parental strains [24,36]. In this regard, we recently
identified functional coding variation in SERT that distin-
guishes these two lines (SERT variation is the same in 129
strains as in DBA2/J) and were able to identify multipleanatomical, biochemical and behavioral traits linked to
this variation [24]. Strain-dependent genetic variation
provides a significant opportunity to identify genetic
background effects on the impact of risk alleles, including
the SERT Ala56 variant.
Biochemical and behavioral assays displayed a striking
divergence of phenotypes between SERT Ala56 knock-in
mice on the 129 versus on the B6 genetic background.
Whereas a few tests showed quantitative differences in
5-HT related biochemical measures on the B6 background
in the same direction as seen for the SERT Ala56 allele
on the 129 background, none of these assays achieved
statistical significance. We suspect that the complexity of
5-HT homeostasis and signaling [37,38], allows variation
in multiple different proteins to moderate the impact of
the SERT Ala56 allele. Importantly, we previously showed
that the native 129 SERT (Glu39) has higher 5-HT uptake
than the Gly39 variant found in the B6 SERT [24]. It is
conceivable that the effect of moving the Glu39 SERT onto
the B6 background is large enough that additional effects
of the Ala56 variant are not detectable. Further studies
directly comparing Glu39 and Gly39 SERTs on a B6
background could shed light on this possibility.
Our findings of genetic background influences on
behavioral measures are consistent with strain-dependent
behavioral phenotypes observed in mouse models of
other ASD-associated genes, most prominently including



















































































Figure 4 Assays of the serotonin system in B6 SERT Ala56 knock-in mice. A) Whole blood serotonin levels (mean, standard error of the mean) in
adult male wildtype littermate control (G/G, n = 6) and homozygous SERT Ala56 (A/A, n = 6) mice; B)Whole blood serotonin levels in male pups at
postnatal day 7 (n = 12 per genotype); C) Synaptosome uptake of 20 nM 3H5-HT during a 5-minute assay at 37°C, (n = 6 per genotype, with 3
replicates for each subject); D) Synaptosome uptake of 100 nM 3H5-HT during a 5-minute assay at 37°C (n = 6 per genotype, with 3 replicates for each
subject); E) Head twitch response to injection of the 5-HT2 agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) during a 15-minute
observation period (n = 12 per genotype); F) Decrease in rectal temperature from baseline in response to injection of the mixed 5-HT1A/7
agonist 8-OH-DPAT (n = 10 per genotype).
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shows variable phenotypes across multiple inbred strains
and hybrid crosses [39]. The NLGN3 R451C knock-in
mouse also shows differences in behavior between mixed
129S/B6 and pure B6 inbred strains [40-42]. Further,
the SERT null mouse also shows variable behavioral
phenotypes across inbred strain backgrounds [43].
The one behavioral phenotype that was consistent
across both genetic backgrounds was the tendency for
SERT Ala56 mice to back away from mice of other geno-
types in the tube test. Not only did the homozygous mu-
tants back out when confronted with wildtype animals,
they also backed away when confronted with heterozy-
gous animals. No difference was seen when heterozygous
animals and wildtype animals were paired, suggesting
that the Ala56 allele only has a significant effect on this
phenotype in the homozygous state. From published
data, the tube test appears to be a very sensitive test of
altered social function in genetic mouse models relatedto ASD, with significant findings in the Fragile X syndrome
model [44], the Rett syndrome model [45], the Arx
((GCG)10+7) infantile spasms model [46], the Potocki-
Lupski model Dp(11)/17/+ mice [47], and the Dhcr7
heterozygous model of Smith-Lemli-Opitz Syndrome
[48]. On the other hand, the tube test may also reveal
significant differences in mice with altered motor function
or impulsivity, or under conditions of social stress [49],
and was originally developed as a test of social hierarchy/
dominance, making it a sensitive but not specific test
for ASD-relevant social behavior. Social interaction in
the tube test does not generate aggression and usually
includes only whisker contact. Dominance in this task
sometimes [50-52] but not always [53] predicts territorial
aggression, and we did not observe any genotype differ-
ences in aggression on the resident-intruder test. We
isolated resident mice for 7 days, and it is possible that a
longer period of social isolation may have generated
more aggression and a potential genotype difference. It
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reflects some genotype difference in social judgment that
is not simply a difference in territoriality or aggression.
Ultrasonic vocalizations on postnatal day 7 also showed
a significant difference between genotypes on the B6 back-
ground, but this difference was in the opposite direction
of that observed on the 129 background. Importantly, B6
animals are well-known to have age-related hearing loss
beginning around 2 to 3 months of age [54], particularly
at higher frequencies, so it is possible that the maternal
response to ultrasonic vocalizations would be altered on
this genetic background. While maternal response could
theoretically interact with pup genotype effects on social
communication, it remains difficult to reconcile these
opposite findings in the SERT Ala56 mice. Of note, some
children with ASD are described as having been passive
infants, with less crying, whereas others are described as
more dysregulated, with more distress and crying [55,56].
Other subtle but significant differences were also found
in the SERT Ala56 mice on the B6 background. Mixed
results in anxiety-like behavior contrast with decreased
anxiety-like behavior in the human SERT over-expressing
mouse (hSERT OE) [57,58]. The attenuation of seroto-
nergic phenotypes in the B6 SERT Ala56 mice may
account for the difference in findings from reports in
the hSERT OE mouse. Alternatively, these discrepant
findings could be due to the difference in mechanism
between increased (hSERT OE) and dysregulated activity
(SERT Ala56 knock-in) [20,21,23].
The male SERT Ala56 mice also show a subtle but
significant decrease in activity in the open field, which
is actually convergent with findings in the hSERT OE
mice, but also in the SERT null mice [43,58,59]. They
do not show changes in locomotion in the home cage
or in the Y maze, however, suggesting that this could
also be a chance finding. A number of potential expla-
nations could explain convergence in activity measures
with increased or ablated SERT activity. Both SERT Ala56
and SERT null mice show a decrease in 5-HT neuron
firing rate [23,60,61]. Further, Jennings and colleagues
showed a loss of frequency sensitivity for evoked 5-HT
release in both hSERT OE and SERT null mice, suggesting
diminished information processing as a convergent
phenotype for opposite disruptions of 5-HT homeostasis
[62]. Multiple examples of convergent phenotypes with
increased or decreased gene dosage or function have
been described in ASD human genetic studies, including
MECP2 deletion and duplication [63-65], chromosome
16p11 deletion and duplication [66], and SHANK3 deletion
and duplication [67].
Conclusions
In summary, the differences between serotonergic phe-
notypes on the 129 and B6 backgrounds suggest thepresence of modifier loci that impact phenotypic expression
of SERTAla56 in mice, consistent with human genetic data.
A cross between these two inbred strain backgrounds
(F2 cross) could be used to identify gene variants that
modify SERT Ala56-dependent phenotypes and could
then be evaluated for epistatic effects with SLC6A4 variants
in human genetic studies. Significant changes in the tube
test, despite little difference in many other behaviors or in
serotonergic assays in adult animals, suggests that this
test of social behavior may be more dependent on SERT
activity or regulation. Possibly, this behavior reflects an
impact of SERT functional alterations during development
that is insensitive to later modifiers that obscure genotype
influences on 5-HT traits in adults. Further studies that
explore the impact of the SERT Ala56 variant during de-
velopment are needed to more clearly identify temporal
epochs through which SERT and 5-HT signaling impact
behavior, as for example with conditional strategies that
institute or limit expression of the variant at different stages
in the life of the animal.
Additional files
Additional file 1: Figure S1. Additional activity, anxiety-like, and social
behavior measures in male B6 SERT Ala56 knock-in mice. A) Distance
traveled (mean, standard error of the mean) in the first 5 minutes in the
open field in wildtype littermate controls (G/G, n = 20), heterozygous
(A/G, n = 16), and homozygous (A/A, n = 20) SERT Ala56 knock-in mice;
B) Number of entries to the open zone of the elevated zero maze; C)
Number of total entries to either the open or the closed zone of the
elevated zero maze; D) Time spent in the familiar social stimulus chamber
(familiar mouse) or novel social stimulus chamber (novel mouse) in the
three-chamber preference for social novelty test for wildtype littermate
controls (G/G, n = 20), heterozygous (A/G, n = 16), and homozygous
(A/A, n = 20) SERT Ala56 mice; E) Time spent within 1 cm of the familiar
or novel social stimulus in the three-chamber preference for social
novelty test. * P < 0.05.
Additional file 2: Figure S2. Activity and anxiety-like behavior in
female B6 SERT Ala56 knock-in mice. A) Time (mean, standard error of
the mean) spent ambulating during the first 5 minutes in the open field
for wildtype littermate controls (G/G, n = 20), heterozygous (A/G, n = 20),
and homozygous (A/A, n = 20) SERT Ala56 mice; B) Time spent in the
center (>1 cm away from the side) of the open field divided by total
time in the open field; C) Time spent in the open zone divided by total
time in the elevated zero maze; D) Time spent in the light chamber
divided by total time in the light–dark test.
Additional file 3: Figure S3. Activity and anxiety-like behavior in
female B6 SERT Ala56 knock-in mice. A) Distance traveled
(mean, standard error of the mean) in the first 5 minutes in the open
field in wildtype littermate controls (G/G, n = 20), heterozygous (A/G),
and homozygous (A/A) SERT Ala56 knock-in mice; B) Number of entries
to the open zone of the elevated zero maze; C) Number of total entries
to either the open or the closed zone of the elevated zero maze.
Additional file 4: Figure S4. Whole blood serotonin levels in P7 female
B6 SERT Ala56 knock-in mice. Whole blood serotonin levels (mean, standard
error of the mean) in female wildtype littermate control (G/G, n = 12) and
homozygous SERT Ala56 (A/A, n = 12) pups at postnatal day 7.
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